Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Bristol Myers Squibb International Corporation
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Randomized, Double-Blind, Phase II Trial of CT-322 (BMS-844203) plus Irinotecan, 5-FU and Leucovorin (FOLFIRI) versus Bevacizumab plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer
The primary objective of the study is to compare the PFS of subjects with metastatic CRC when treated with CT-322 (BMS-844203) in combination with FOLFIRI chemotherapy versus bevacizumab in combinatio...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept vs. Placebo on a Background of Oral Glucocorticosteroids in the Treatment of Subjects with Systemic Lupus Erythematosus and the Prevention of Subsequent Lupus Flares. Revised Protocol Number 02: Incorporates Amendments 2 & 3 - Protocol Amendment 1 - Site Specific
The primary objective for this study will be to assess the proportion of subjects with a new clinical flare of SLE (BILAG “A” or “B”) during the 1 year double-blind treatment period, comparing abatace...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Phase IV, Open-Label, Randomized, Multicenter Trial Assessing the Efficacy of a Treatment Maintenance Phase with Unboosted vs. Boosted Reyataz After an Induction Phase with Reyataz and Ritonavir in Treatment Naive HIV Patients Revised Protocol 03 Incorporating Protocol Amendments 02, 04 and 06 (Version 1.0, Date 19-June-2007)
To compare the proportion of subjects with HIV-1 RNA viral load < 50 c/mL through Week 48 of the Maintenance Phase among HIV-infected subjects with an initial undetectable viral load on an ATV/RTV con...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Phase II Study of Dasatinib (BMS-354825) for Advanced ‘Triple-negative’ Breast Cancer + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 2.0 dated 16-Aug-06) + Pharmacogenomics Tissue Sample Amendment Number 02 - Site Specific - (version 1.0 dated 16-Aug-06)
To estimate objective response rate (ORR) of dasatinib in women with recurrent or progressive locally-advanced or metastatic 'triple-negative' breast cancer.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
An open-label, randomized study of dasatinib vs. high-dose (800 mg) imatinib in the treatment of subjects with chronic phase chronic myeloid leukemia who have had a suboptimal response after at least 3 months of therapy with 400 mg imatinib. Revised Protocol 03, incorporating Administrative Letter 01 and Protocol Amendments 02 (Version 1.0, Dated 29-May-2007), 03 (Version 1.0, Dated 10-Oct-2007) and 04 (version 1.0, dated 10-Apr-08)
The primary objective of this study is to compare the rate of major molecular response of dasatinib (100 mg QD) to high-dose imatinib (800 mg, i.e. 400 mg BID) therapy at 12 months in chronic phase CM...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as first Line Therapy for Locally Recurrent or Metastatic Breast Cancer. Ensayo clínico fase II, abierto, aleatorizado con tres brazos de tratamiento de 2 esquemas de la combinación de ixabepilona y bevacizumab frente a la de paclitaxel y bevacizumab como primera línea de tratamiento del cáncer de mama tras recaída local o metastásica Revised Protocol 01, Incorporating Protocol Amendment 01 (Version 1.0, Date 07-Dec-2006). And Pharmacogenetics Blood Sample Amendment 02 - Site Specific (Version 2.0, Date 12-Dec-2006)
To estimate the response rate of ixabepilone/bevacizumab combination in each of the following 2 schedules relative to the reference arm of paclitaxel plus bevacizumab: • Ixabepilone administered every...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Randomized, Open label, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068 in HIV-1 Infected Subjects
To assess the antiviral activity of BMS-626529 following administration of selected regimens of BMS-663068 with and without Ritonavir (RTV) administered orally to HIV infected subjects for 8 days.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-955176 and BMS-955176 with Atazanavir +/- Ritonavir in HIV-1 Infected Subjects
Primary Objective is to assess the antiviral activity in HIV-1 infected subjects following administration of BMS-955176 for 10 days.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolar I Disorder Patients Treated with Valproate or Lithium and in Need of Further Clinical Improvement. Revised Protocol 02, Incorporating Administrative Letters 01 and 02 and Amendment 02 (v2.0, dated 17-oct-2008) Studio di 12 settimane multicentrico, randomizzato, in doppio cieco, controllato verso placebo per valutare l`efficacia e la sicurezza dell`aggiunta di Aripiprazolo nel trattamento di episodi maniacali in pazienti affetti da Disturbo Bipolare di Tipo I gia` in trattamento con Litio o Valproato e che hanno bisogno di un ulteriore miglioramento.Protocollo Revised 01 che incorpora l`Amministrative Letters 01 e 02 e l`emendamento 02 (v2.0 del 17-10-2008)
To evaluate the efficacy of adjunctive treatment with aripiprazole compared to placebo, as measured by YMRS, in the treatment of Bipolar I Disorder Mania subjects treated with valproate or lithium and...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A study for people with Type 2 Diabetes to see how safe and effective different drug combinations are for this disease. The combinations are saxagliptin and dapagliflozin added to metformin, saxagliptin added to metformin, or dapagliflozin with metformin
To compare the mean change from baseline in glycosylated hemoglobin (HbA1c) achieved with concurrent addition of saxagliptin and dapagliflozin to metformin versus the addition of placebo & saxagliptin...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant